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Atrial natriuretic peptide and dopamine in a rat model of
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Atilal natriuretic peptide and dopamine in a rat model of lschemic
acute renal failure. Atrial natriuretic peptide (ANP) has been shown to
reverse experimental models of ischemic acute renal failure (ARF).
However, infusion of ANP has been associated with systemic hypoten-
sion making its use in clinical ARF impractical. Therefore, in this
investigation, dopamine (D) was combined with intravenous (i.v.)
atriopeptin III (AP III) to determine if this regimen was effective in
reversing ARF while preventing systemic hypotension and maintaining
renal blood flow (RBF). Four groups of Munich-Wistar rats were
studied. Group I, sham-ARF; Group 2, renal artery (RA) clamp (55
mm) followed by i.v. saline; Group 3, RA clamp followed by i.v. AP
III-D; and Group 4, RA clamp followed by iv. D only. All infusions
were begun after RA clamp release and continued for four hour. Mean
arterial pressure in Group 3 rats given AP llI-D were similar to that in
Group 2, slightly less than that in Groups I and 4 (P < 0.05), but
consistently >100mm Hg during the four hour infusion, RBF in Group
3 was elevated above the level in Group 1 at P < 0.05. Glomerular
filtration rate (GFR), depressed by 52% in Group 2, was corrected to
control (sham-ARF) levels in Group 3. In Group 4 there was a small but
significant increase in GFR compared to Group 2 (P < 0.05), but it
remained less than that in sham-ARF or AP II1-D treated ARF rats (P
< 0.01). Urine flow rate and urine sodium excretion rate were more
than sixfold higher in Group 3 than any other group. Micropuncture
measurements revealed single nephron glomerular filtration rate
(SNGFR) in Group 3 to be twice that in Group 2 and actually greater
than sham-ARF rats (P < 0.05), while it remained similar to Group 2 in
the Group 4 rats. The increase in SNGFR in the APIII-D treated ARF
rats was due to marked increases in both glomerular capillary hydraulic
pressure (P0) and glomerular plasma flow rate (QA) as the result of a
major decline in afferent arteriolar resistance (RA) compared to the
other three groups. It was concluded that the combination of i.v. AP III
and D is effective in restoring GFR in an ischemic model of ARF while
preventing systemic hypotension and maintaining RBF. The dominant
effect on glomerular hemodynamics, attributable primarily to AP III,
was a reduction in RA causing striking increases in both P0 and QA.
Recent animal studies have shown that the effects of acute
renal ischemia can be reversed by infusion of atrial natriuretic
peptide (ANP). Nakamoto et al [1] significantly increased inulin
clearance (CIN), urine flow rate (V) and tubular sodium reab-
sorption in both the isolated perfused and in vivo rat kidney
with intravenous atriopeptin III (AP III) after 60 minutes of
renal artery occlusion (RAO). Shaw et al [2] and Schafferhans et
al [3] also have corrected acute renal dysfunction using intra-
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renal ANP following ischemic injury induced by RAO or
norepinephrine in rats. While these studies suggest the possi-
bility that clinical acute renal failure (ARF) could be reversed
by pharmacological infusion of ANP, therapeutic enthusiasm
has been tempered by the observation that a marked reduction
in arterial pressure may be associated with ANP infusion. With
intravenous doses of AP III effective in restoring renal function,
Nakamoto et al [1] reported that mean systemic arterial pres-
sure (MAP) fell to approximately 70 mm Hg. Arterial pressures
were not given in the studies of Shaw et al [2] and Schafferhans
et al [3]; however, it is possible that arterial pressure reductions
were encountered since both the intrarenal infusion rates and
total ANP doses were greater than those used by Nakamoto et
al [11. A number of other studies also have shown a substantial
reduction in arterial pressure in both humans and experimental
animals at infusion rates of ANP comparable to those that have
been efficacious in acute renal ischemia 14, 5]. Thus, given the
tenuous hemodynamic status of many ARF patients, the clinical
potential of ANP could be limited unless the associated reduc-
tion in arterial pressure is prevented.
In the present study, we tested the effects of the combined
use of ANP and dopamine (D) intravenously following 55
minutes of bilateral renal artery clamping in Munich-Wistar
rats. ANP was given at a dose previously shown to be neces-
sary to improve ischemic injury but reduce MAP [11 and
dopamine was given at a dose sufficient to prevent the reduction
in MAP without compromising renal blood flow. The effect on
both whole kidney function and glomerular dynamics was
measured after four hours of this treatment regimen and com-
pared to that of saline infusion or dopamine alone.
Methods
Littermate male Munich-Wistar rats weighing between 250
and 300 g were prepared for whole kidney clearance and
micropuncture studies as described elsewhere [6, 71. Following
pentobarbital anesthesia (60 mg/kg i.p.), a tracheostomy was
performed and catheters were placed in the left jugular and
femoral veins and femoral artery. The left kidney was exposed
through a flank incision, dissected free from surrounding tissue
and placed in a lucite cup. The femoral vein catheter was
advanced into the left renal vein by a technique described
previously for this laboratory [81. The left ureter was catheter-
ized for urine collections. Arterial blood pressure was continu-
ously monitored with an electronic transducer (Statham model
P23Db, Gould, Inc., Oxnard, California, USA) and a direct
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writing recorder (model 7702B, Hewlett-Packard Co., Palo
Alto, California, USA).
Rats were then divided into four experimental groups as
follows:
Group 1: (N = 6) Sham-ARF time-controlled animals
Following manipulation and dissection of the renal pedicle
from surrounding tissue, an intravenous infusion of 0.9 per cent
saline was given at 1.5 mI/hr for 55 minutes. Thereafter, the
infusion rate was increased to 2.8 mI/hr for four hours. Three
hours into infusion, inulin and para-aminohippurate (PAH)
were added to give plasma levels of 50 to 100 and 2 to 4 mg/dl,
respectively. At the end of the four-hour infusion, tail vein and
renal venous blood samples were obtained between 50-pi timed
urine collections for measurement of sodium, inulin and PAH.
Thereafter, at least five two-minute collections of proximal
tubular fluid were made with 8 m outside diameter oil-filled
pipettes. In order not to introduce examiner bias, individual
nephrons to be studied were chosen by accepting the tubule
which lay beneath a cross-hair placed in the ocular of the
microscope. Subsequent nephrons were selected in the same
manner after shifting blindly to a new microscopic field. With a
servo-null pressure monitoring device (Instruments for Physi-
ology and Medicine, San Diego, California, USA), an electronic
transducer (Statham model P23Db, Gould, Inc.), hydraulic
pressures were measured in glomerular capillaries (PGC), ef-
ferent star vessels (PE), and proximal tubules (PT). At least
three measurements were made in each animal. Because it was
discovered that dopamine in plasma samples factitiously in-
creases intensity of both the phthalaldehyde flurometric [9] and
Lowry colormetric [10] measurements of microprotein concen-
tration, whole kidney filtration fraction derived from inulin
extraction was used as an estimate of single nephron filtration
fraction (SNFF). Comparison of SNFF determined from femo-
ral artery and efferent arteriole plasma protein by the phthalal-
dehyde technique with whole kidney FF in rats not infused with
dopamine revealed the latter to be consistently 5 to 10 per cent
lower. However, the magnitude of animal to animal differences
were identical. Therefore, because of the minimal absolute
differences in individual animals and the same inter-animal
differences using the two determinations of filtration fraction,
substitution of whole kidney for single nephron value was
considered justified. Afferent arteriolar protein content (CA)
was determined from the direct biuret measurement of femoral
artery plasma protein [11] which was not altered by dopamine.
Efferent arteriolar protein content (CE) was calculated from the
femoral artery protein content and the whole kidney filtration
fraction. This technique has been used previously by our
laboratory [8] and other investigators [12, 131. At the conclusion
of the micropuncture measurements, tail and renal vein blood
and timed urine collections were repeated for sodium, inulin
and PAH. If the pre- and post-micropuncture values of urinary
sodium excretion rate (UnaV), inulin clearance (CIN), and
para-aminohippurate clearance (CPAH) (adjusted for extraction
fraction) differed more than 10 per cent, the experiment was
discarded.
Group II rats: (N = 6) Saline-treated ARF controls
Except for 55 minutes of bilateral renal artery clamping prior
to the four hours of 0.9 per cent saline infusion, these animals
were treated identically to Group I. Infusion rate was adjusted
every 30 minutes to match urine flow rate (V).
Group III rats (N = 6)
These animals underwent the same protocol as Group II, but
were infused with AP III (Bachem, Inc., Torrance, California,
USA) at 0.2 sg/kg/min, the dose that reversed ischemic injury
but lowered MAP in the study of Nakamoto Ct al [1], and D
(Lypho Med., Inc., Melrose Park, Illinois, USA) at a rate
sufficient to maintain MAP > 100 mm Hg following the 55
minutes of bilateral renal artery clamping. Infusion varied from
0.8 to 9.0 sg/kg min'. As in Group II, 0.9 per cent saline
infusion was adjusted every 30 minutes to match V.
Group IV rats: (N = 6) Dopamine controls
Rather than a combined infusion of AP III and D, only D was
infused for four hours following 55 mm bilateral renal artery
clamping. D was infused at a maximal dose that did not elevate
MAP above 120mm Hg and ranged from 0.4 to 1.6 g/k min';
however, D could not be infused at the upper end of infusion
range when given with AP III without producing MAP above
120 mm Hg.
AP III alone was not infused because of the profound
reduction in MAP found in preliminary studies negating mean-
ingful comparisons of micropuncture results and because these
experiments had previously been performed by others [2, 3] and
were considered to be an adequate basis for comparison with
the present study.
Analytic techniques
Plasma and urine inulin and PAH were measured with a
Technicon Autoanalyzer (Technicon Instruments Corp., Tarry-
town, New York, USA). Tubular fluid inulin was estimated by
the micromethod of Vurek and Pegram [14] as modified for this
laboratory [10]. Urinary sodium concentration was determined
by flame photometry.
Plasma colloid osmotic pressure (IT)was determined from the
Landis and Pappenheimer formula [15]:
1r(mm Hg) = 2.1C + 0.16 C2 + 0.001 C3
where C represents total protein concentration (in grams per
deciliter).
Single nephron filtration rate (SNGFR) was calculated from
the formula:
SNGFR = CR x TF/PIN
where CR represents tubular fluid collection rate and TF/P1 the
tubular fluid to plasma inulin ratio.
Proximal tubular absolute reabsorption (J) was estimated
from the expression:
= SNGFR — CR
Proximal tubular fractional reabsorption (FR) was calculated
FR = JV/SNGFR
as:
Single nephron filtration fraction (SNFF) was calculated from
the equation:
SNFF = 1 — (CA/CE)
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Table 1. Whole kidney function parameters
Group
Body wt
g
Hct
vol %
MAP
mm Hg
RBF GFR v
pJ/min
UNaV
pEqimin
FENa
%mi/mm
I Sham-ARF 295 23 55 1 111 4 6.93 0,92 0.720 0.077 12 5 0.24 0.12 0.22 0.13
controls (6)
2 ARF-saline (6) 277 24 55 2 104 4 5.32 1.74 0.351 0.082 7 2 0.58 0.04 1.16 0.07
3 ARF-AP III-D 275 16 58 4 102 6 9.73 2.04 0.785 0.070 101 57 8.02 0.56 7.01 0.46
(6)
4ARF-D(6) 286 10 58 1 114 3 8.63 1.43 0.496 0.066 16 9 1.54 0.19 2.13 0.43
F, 1 vs. 2 NS NS <0.05 NS <0.01 NS <0.01 <0.01
F, 1 vs. 3 NS NS <0.05 <0.05 NS <0.01 <0.01 <0.01
F, 1 vs. 4 NS <0.01 NS NS <0.01 NS <0.01 <0.01
F, 2 vs. 3 NS NS NS <0.01 <0.01 <0.01 <0.01 <0,01
F, 2 vs. 4 NS <0.05 <0.01 <0.01 <0.05 NS <0.01 <0.01
F, 3 vs. 4 NS NS <0.01 NS <0.01 <0.01 <0.01 <0.01
Values are means SD. Numbers in parentheses are numbers of rats. Abbreviations are: body wt, body weight; Hct, arterial hematocrit; MAP,
mean arterial pressure; RBF, renal blood flow; GFR, whole kidney glomerular filtration rate; V, urine flow rate; UNaV, urinary sodium excretion
rate; FENU, fractional excretion of sodium.
where CA and CE denote afferent and efferent arteriolar protein
concentrations, respectively, based on femoral artery protein
content and the whole kidney filtration fraction derived from
inulin extraction.
Glomerular plasma flow rate was QA = SNGFR/SNFF where
QA refers to glomerular plasma flow rate.
Blood flow rate per single afferent arteriole or glomerulus was
calculated as GBF = QA/(l — HctA) where HctA, the hemato-
crit of afferent arteriolar blood, was taken to be equal to the
femoral arterial hematocrit.
Efferent arteriolar blood flow rate was determined as:
EABF = GBF — SNGFR
Resistance per single afferent arteriole was derived from the
formula:
= [(MAP — P03/GBF] X (7.962 X 1010)
where the factor 7.962 x 1010 is used to give resistance in units
of dynes/sec/cm5 when MAP and P0 are expressed in millili-
ters of mercury and GBF in nanoliters per minute.
Resistance per single afferent arteriole was derived from the
formula:
RE [(0 — PE)/EABFI x 7.962 x l0'°
where E is the pressure recorded in the efferent "star" vessel.
Mean glomerular transcapillary pressure difference was cal-
culated as:
AP = GC —
The ultrafiltration coefficient (Kf) was determined by the
block iteration described by Blantz [16].
Data are expressed as means SD. Overall group compari-
sons were by analysis of variance for multiple groups and
individual intergroup comparisons were by Dunnett's method
when comparing ARF groups to the sham-ARF control group,
and Scheffe's method when comparing ARF groups to each
other [17],
Results
Body weights, hematocrits, mean arterial blood pressures
and whole kidney function parameters are shown in Table 1.
Body weights are similar in all groups. Mean hematocrit was
slightly higher in the D-treated ARF rats than in the sham-ARF
control or saline-treated groups. Mean arterial pressure was
maintained > 100 mm Hg during the four hour infusion in the
AP III-D treated ARF rats. This MAP level was not different
from that in the saline-treated animals. Both sham-ARF control
and D-treated ARF rats had significantly higher MAP than the
saline and AP HI D-treated ARF groups. In both NP III-D and
D-treated ARF rats RBF was increased compared to the
saline-treated ARF group. RBF was also higher in the AP III-D
treated ARF than the sham-ARF control group. RBF in the
saline-treated ARF rats had recovered to the same level as in
sham-ARF controls. Mean GFR was 48 per cent of that in
sham-ARF controls in the saline-treated ARF animals but was
increased to that in sham-ARF control rats in the AP III-D
group. While GFR in the D-treated ARF group was slightly
greater than that in saline-treated ARF rats, it remained signif-
icantly lower than that in AP III-D infused ARF animals. Urine
flow rate was strikingly increased in the AP III-D ARF animals.
The mean level of V was more than sixfold greater than
sham-ARF controls or the other two ARF groups. Urinary
sodium excretion rate (UNaY) was also markedly increased in
the AP III-D treated ARF rats as was the fractional excretion of
sodium (FENa). Glomerular filtration rates, urine flow rates and
urine sodium excretion rates are illustrated in Figure 1.
Micropuncture studies are shown in Table 2. Single nephron
glomerular filtration rate was reduced by 40 per cent in saline-
treated ARF rats compared to sham-ARF controls. In the AP
III-D treated ARF rats, however, SNGFR not only was higher
than in saline-treated ARF rats but was actually greater than in
the sham-ARF control animals. The SNGFR in the D-treated
ARF group was not different from the reduced level in saline-
treated ARF rats.
Of the determinants of SNGFR, elevations in both SP and QA
were responsible for the increase in SNGFR in the AP III-D
treated AFR animals. The AP level was due primarily to an
increased P0, which was 17 mm Hg higher than the sham-ARF
control value, and at least 10 mm Hg greater than the cone-
sponding mean GC in saline-treated and D-treated ARF rats.
Glomerular plasma flow was nearly 100 nllmin greater than that
in sham-ARF or other ARF treatment groups. In the D-treated
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Urine flow rate Sodium
excretion rate
Fig. 1. Giomerular flit ration rates, urine flow rates and urine sodium
excretion rate in sham-ARF () and ARF rats treated wit/i saline (),
atrial natriuretic peptide-dopamine () and dopamine only (0).
*Different from corresponding value in other ARF groups at P < 0.01.
ARF group, P0c was higher than in sham-ARF rats, but mean
was similar due to the variable tendency for P1- to be
increased in ARF rats. Comparative SNGFR. GC, T and QA
values are shown in Figure 2.
The marked increases in P0c and QA in the AP III-D treated
ARF rats were due primarily to changes in RA. RA was
strikingly lower than in the other three groups. Mean R in AP
III-D treated ARF rats tended to be lower than that in saline-
treated ARF rats; however, the difference was not significant.
RE in AP III-D treated group also was not significantly less than
in sham-ARF or D-treated ARF animals. There were no differ-
ences inKF values among any of the four experimental groups.
Since i.W was greater than ir in all groups, all Kf determina-
tions represented unique values.
Efferent star vessel hydraulic pressure, as an index of efferent
arteriolar pressure (PE)' was significantly elevated in AP III-D
treated ARF rats. All other group means of E were similar.
Absolute proximal reabsorption was lower in saline-treated
ARF rats than in sham-ARF controls. However, no other
significant differences in iv were detected. Means of proximal
tubular fractional reabsorption tended to be lower in the AP
III-D and D-treated ARF rats. However, the animal to animal
variability within the groups negated detection of overall or
pairwise significant comparative differences.
Discussion
Atrial natriuretic peptide has been shown to have exciting
potential in reversing the effects of acute renal ischemia [1—3].
However, the systemic hypotensive effect of this agent may be
a drawback to its clinical use [1, 4, 51. The present study
demonstrates that the combination of ANP and dopamine can
correct the decrement in GFR induced by 55 minutes of RAO
while maintaining mean arterial pressure above 100 mm Hg.
The parenteral infusion of ANP and dopamine may be a
practical as well as efficacious combination in the treatment of
ischemic ARF, since it can be employed after, rather than
before, the ischemic insult and it does not alter systemic
hemodynamics, which is a major concern in the clinical setting.
The results indicate that while dopamine was responsible for
supporting systemic arterial pressure, AP III was of greater
significance in reversing the ischemia-induced reduction of
GFR. Dopamine given alone in a dosage range similar to that
used when combined with AP III significantly increased both
RBF and GFR when compared to ARF rats treated with saline
only. However, the improvement in GFR with dopamine was
less than one-third of that with AP III and D combined. Mean
GFR with the combined AP III-D treatment was actually
greater than in sham-ARF control animals. The improvement in
GFR with ANP following renal ischemia to levels the same as or
r::
higher than non-ischemic controls has been reported previously
by other investigators [1, 3].
_____
The mechanism of elevation of post-ischemic GFR by AP
III-D was clarified by the experiments measuring glomerular
dynamics. There were marked increases in both GC and QA
that resulted in a greater than twofold increase in SNGFR
compared to the saline-treated ARF rats. While zP would
generally play a greater and QA a lesser role in the filtration
disequilibrium conditions found in this study [18], the magni-
tude of increase in QA accounted for nearly one-half of the
SNGFR increase. The changes in both P and QA in AP III-D
treated ARF animals were due primarily to a profound reduc-
tion in RA. Afferent arteriolar resistance was not increased in
saline-treated ARF rats four hours after blood reflow compared
to sham-ARF controls, indicating that there was not a marked
increase in vasoconstrictor activity at this site. Nonetheless,
infusion of AP III-D resulted in a 60 per cent reduction in mean
RA even though the vasodilator effect of ANP had been noted
previously to be most profound in angiotensin or norepineph-
rifle pre-constricted vessels [19]. While it is possible that the
substantial decrease in RA in this study was due to a synergistic
effect of dopamine with AP III, dopamine alone in the doses
that were used did not reduce afferent arteriolar resistance and,
therefore, it must be assumed that AP III was the dominant
factor in afferent arteriolar relaxation. In preliminary experi-
ments, dopamine alone given at the highest levels as when
combined with AP III actually caused an increase in RA
compared to normal controls. Efferent arteriolar resistance in
AP III-D treated ARF rats was not different from that in
saline-treated ARF animals. Direct measurements by Ichikawa
et al [20] in normal rats have indicated that R was increased by
ANP. However, the effect of dopamine combined with AP Ill
may have attenuated an ANP-induced elevation of RE. On the
A
B
Glomerular
filtration rate
*
*
160
120
.5
80
40
C
8
6
4
2
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Table 2. Individual nephron measurements of glomerular and tubular dynamics
Treatment
group
SNGFR
ni/mm
Z3 T 1E
SMFF
A E
mm Hg
QA
ni/mm
RA RE
x 10'°dynes/sec/cm5
Kr
nl/sec/
mm Hg
Jv
ni/mm
FR
%mm Hg
1 Sham-ARE 35 48 11 15 37 0.25 16 25 149 1.52 0.88 0.0338 17 49
controls (6) ±7 ±2 ±1 ±1 ±2 ±0.05 ±1 ±3 ±45 ±0.43 ±0,28 ±0.0083 ±5 ±10
2 ARF-saline (6) 21
±4
52
±7
19 16
±8 ±4
33
±6
0.15
±0.08
17 27
±2 ±8
145
±43
1.26 0.95
±0.38 ±0.34
0.0320
±0.128
10
±2
47
±6
3 ARF-AP 49 65 22 23 43 0.23 16 22 241 0.52 0.65 0.0376 19 40
III+D (6) ±9 ±4 ±5 ±3 ±4 ±0.06 ±2 ±3 ±44 ±0.30 ±0.24 ±0.0171 ±8 ±13
4ARF-D(6) 23
±9
54
±5
21 17
±10 ±4
33
±6
0.16
±0.05
15 20
±2 ±3
150
±43
1.34 0.84
±0.50 ±0.31
0.0231
±0.0101
10
±6
43
±12
P. 1 vs. 2 <0.01 NS NS NS NS NS MS NS NS NS MS NS <0.01 NS
F, 1 vs. 3 <0.05 <0.01 <0.01 <0.01 <0.05 NS NS NS <0.01 <0.01 NS NS MS MS
P, 1 vs. 4 MS MS NS NS NS <0.01 MS <0.05 NS MS MS MS NS NS
P, 2 vs. 3 <0.01 <0.01 MS <0.05 <0.05 MS MS MS <0.01 <0.01 MS NS NS NS
P,2vs.4 MS MS MS MS NS NS NS MS NS NS NS MS MS MS
P, 3 vs. 4 <0.01 <0.01 NS <0.05 <0.05 NS MS NS <0.01 <0.05 MS MS NS NS
Values are means ± so. Mumbers in parentheses are numbers of rats. Abbreviations are: SNUFR, single nephron glomerular filtration rate; POC,
glomerular capillary hydraulic pressure; T' proximal tubular pressure; E, efferent star vessels; SF, net hydraulic ultrafiltration; SMFF, single
nephron filtration fraction; afferent arteriole colloid pressure; TE' efferent arteriole; QA' glomerular plasma flow; RA, resistance per single
afferent arteriole; RE, resistance per single efferent arteriole; K, ultrafiltration coefficient; J,,,, proximal tubule sodium reabsorption; and FR,
proximal tubular fractional reabsorption.
other hand, it should be noted that the absence of a significant A
decrease in Rt was itself a contributing factor in the increase in
P6c in addition to the aforementioned reduction in RA.
There was an increase in whole kidney GFR but no change in
0 SNGFR in the D-treated ARF animals. While this difference6
may reflect a sample size error in the latter measurement, the
consistency of this difference in all rats suggests a relative .
redistribution of renal blood flow to sub-surface nephrons
secondary to dopamine as has been found with other vasodila-
tors [21].
The mechanism of the striking natriuresis observed in the AP 20
II!-D treated ARF rats was likely complex in a post-ischemic
model with tubular injury. While the increase in GER was, no
doubt, a major factor in the natriuresis, tubular dysfunction and
direct effects of AP HI probably contributed as well. In exper-
imental animals with normally functioning tubules, a doubling B
of GFR is associated with only a two- to fourfold increase in
sodium excretion, indicative of whole kidney glomerulo-tubular 60
balance [22]. However, in the AP III-D treated ARF rats in this
study where there was a doubling of GFR compared to saline-
treated ARF animals, sodium excretion increased 14-fold. It is 40
not possible to separate clearly the effects on tubular sodium
reabsorption of ANP or D from those of ischemic damage. On E
the other hand, the markedly greater fractional, as well as 20
absolute, sodium excretion in the AP III-D treated ARF rats
compared to both the saline and D-treated ARF groups suggests
strongly that there was a direct effect of AP III to decrease
tubular sodium reabsorption. The natriuretic effect of AP III in
this ARF model was beyond at least the accessible proximal
convoluted tubule, since neither absolute nor fractional reab-
sorption of sodium in the proximal tubule differed among the
ARF groups treated with saline, AP III-D or D alone. However,
the tendency for decreased fractional volume reabsorption in
the accessible proximal convoluted tubule coupled with an
increased P in the AP III-D treated ARF rats suggests that
Sihgle nephron
glomerular
filtration rate
C
Glomerular capillary Glomerular plasma
and tubular pressure flow rete
Fig. 2. Single nephron glomerular filtrate rates, glomerutar capillary
(left) andproximal tubular (right) pressures and glomerular plasma flow
rates in sham-ARF (LI) and ARF rates treated with saline (a),
atriopeptide Ill-dopamine (•) and dopamine only (13). The difference
between glomerular capillary and proximal tubular pressure is the net
glomerular transcapillary hydraulic pressure. *Different from corre-
sponding value in other ARF groups at P < 0.01.
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peritubular capillary hydraulic forces may have played a role in
decreasing volume reabsorption in the late proximal tubule
beyond the micropuncture sites. Recent reports in normal rats
also indicate that there is a substantial tubular effect of ANP
beyond the proximal convoluted tubule and most likely is in the
loop of Henle, collecting tubules and collecting ducts [23, 24].
Dopamine also has been associated with a natriuresis that is
independent of RBF or GFR [25]. The contribution of dopamine
to the natriuresis induced by AP III-D, however, was probably
small, as indicated by the absolute and fractional sodium
excretion in the D-treated ARF rats which were much less than
with the combined AP III-D infusion.
In addition to the maintenance of systemic MAP, the combi-
nation of ANP and dopamine may have relatively specific
beneficial effects on at least two of the most frequently reported
pathogenetic mechanisms reducing GFR in ischemic ARF,
namely, tubular obstruction [26] and increased renovascular
resistance [27]. Tubular obstruction decreases glomerular filtra-
tion by increasing proximal tubular pressure and lowering the
net transcapillary hydraulic pressure. ANP, which is reported
to increase GC by decreasing RA and increasing RE, elevates
the net transcapillary hydraulic pressure [20]. On the other
hand, ANP alone does not consistently decrease total renovas-
cular resistance because of the reciprocal effects on pre- and
postglomerular resistances and, therefore, does not increase
glomerular plasma flow [20]. However, dopamine appears to
attenuate the efferent arteriolar vasoconstriction and possibly
enhances the afferent arteriolar vasodilatation induced by ANP,
thereby increasing glomerular plasma flow. Thus, ANP plus
dopamine directly increases two of the determinants of glomer-
ular ultrafiltration, namely, transcapillary glomerular hydraulic
pressure and glomerular plasma flow, that are depressed by the
pathogenetic processes in ischemic ARF.
This study did not address the post-infusion intermediate or
long term effects of ANP and dopamine in ARF, since the thrust
of the experiments was to examine the compatibility and
physiologic effects of combining those agents and the support-
ive role of dopamine in ANP therapy to reverse ARF. How-
ever, in the studies of Shaw et al [2] and Nakamoto et al [1] in
which ANP was infused for from one to four hours after 45 to 60
minutes of renal artery clamping, serum creatinines were nor-
mal at 24 and 48 hours, respectively, compared to three- and
fourfold increases in untreated ARF rats. Moreover, the former
study [2] showed marked improvement in the histologic appear-
ance at 48 hours, particularly inner cortical and outer medullary
peritubular hyperemia. On the other hand, the presence of
tubular casts was not significantly changed. Since the AP III-D
infusion in the present investigation showed nearly identical if
not slightly greater immediate improvements in GFR and urine
flow rate compared to the above studies [1, 2], it is reasonable
to assume that the post-infusion course would have been
similarly impressive.
In summary, the addition of dopamine in the treatment of
ischemic ARF effectively corrects the systemic hypotensive
effect of ANP that could impede its clinical use in attenuating
the course of ARF. Moreover, dopamine may also enhance the
positive effects of ANP on the determinants of glomerular
ultrafiltration. Thus, ANP and dopamine infusion potentially
may be a therapeutically beneficial combination in human
ischemic ARF. This combined intravenous maneuver avoids
the invasive intrarenal infusion of ANP; the hypotensive effect
of ANP and dopamine also appears to enhance the protective
effect of ANP in experimental ARF.
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